Core Insights - The article highlights the successful angel round financing of Lide Health Technology, raising nearly 100 million RMB, marking the largest angel financing in the life sciences and bio-manufacturing equipment sector in the past three years [2] - Lide Health, established in October 2023, focuses on AI and high-end life science instruments, aiming to provide microfluidic, automation, and intelligent system-level solutions for various fields [4] - The company has signed a cooperation agreement with Guangzhou Laboratory for the transformation of 22 patents, including several PCT international patents and invention patents, and has independently applied for 57 patents and 10 software copyrights [4] Company Overview - Lide Health is headquartered in Guangzhou International Biological Island and specializes in the research and development of high-end life science instruments and bio-manufacturing equipment [4] - The company has quickly achieved commercialization of technological achievements, signing commercial orders exceeding 10 million RMB with leading clients in 2024 [4] Core Technologies and Products - Lide Health's core technologies span microfluidic chips, life sciences, biopharmaceuticals, medical devices, robotic automation, and artificial intelligence [5] - The company has developed a series of proprietary products, including a single-cell multi-omics system and a high-throughput AI imaging flow cytometer, which are crucial for life science research and biopharmaceuticals [5][6] - The active single-cell sequencing system is a pioneering product in the industry, featuring active coding sorting technology and excellent sample compatibility [5] Upcoming Events - The article mentions several upcoming global medical technology conferences organized by Suyu, including the first Global Aesthetic Technology Conference on June 12, 2025, and the second Global Medical Technology Conference on July 17, 2025 [1][7]

Core Viewpoint - Lide Health has successfully completed nearly 100 million yuan in angel round financing, focusing on AI + life science instruments and biopharmaceutical equipment development, aiming to break foreign technology monopolies and receiving support from several well-known institutional investors [1][2]. Financing and Market Opportunity - The financing round was led by Jia Dao Capital, with participation from Qi Ji Investment, Zhongke Chuangxing, Ju Ke New Emerging Industry Venture Capital, Jian Shi New Intelligence Investment, and Jiu Zhou Xin Nuo. The funds will be used to accelerate technology research and development, product industrialization, and market expansion [2]. - The global scientific instruments and biopharmaceutical equipment market is vast, but China faces a domestic production rate of less than 20%, indicating a significant opportunity for domestic breakthroughs [2]. Company Overview and Product Development - Founded in October 2023, Lide Health is a benchmark hard-tech startup in Guangzhou focused on the independent research and development of AI + high-end life science instruments and biomanufacturing equipment [3]. - The company has developed a comprehensive ecosystem including AI algorithms, biochips, and reagent consumables, with a product lineup that includes ten products such as single-cell multi-omics systems and high-throughput AI imaging flow cytometers [3]. Team and Intellectual Property - The core team includes experts from Huawei and medical device technology specialists, with over 70% of the team dedicated to product research and development [4]. - Lide Health has signed a cooperation agreement for the transformation of intellectual property with Guangzhou Laboratory, converting 22 patents and applying for 57 additional patents and 10 software copyrights [4]. Partnerships and Market Engagement - The company has signed technical service contracts with top hospitals and equipment contracts with leading universities and biopharmaceutical companies, securing over 10 million yuan in commercial orders in 2024 [5]. - The CEO emphasized that this financing not only provides sufficient funds for R&D and product industrialization but also reflects the capital market's recognition of Lide Health's direction in the life science instruments and biomanufacturing equipment sector [5]. Investor Insights - Investors from Jia Dao Capital and Qi Ji Investment expressed confidence in Lide Health's technological strength and innovation potential, anticipating significant value creation and market expansion [6].